『Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions』のカバーアート

Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions

Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.
まだレビューはありません